-
Income Statement
-
Balance Sheet
-
Cashflow Statement
-
Profitability
-
Ratios
Thermo Fisher Scientific Income Statement
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Revenue |
|
$32.22B | $39.21B | $44.92B | $42.86B |
| Cost of Revenue |
|
$15.71B | $18.98B | $25.42B | $25.74B |
| Gross Profit |
|
$16.51B | $20.23B | $19.50B | $17.11B |
| Research & Development |
|
$1.18B | $1.41B | $1.47B | $1.34B |
| Selling,General & Administrative |
|
$5.76B | $6.84B | $7.13B | $8.45B |
| Operating Expense |
|
$8.61B | $10.01B | $10.99B | $10.25B |
| Operating Income |
|
$7.79B | $10.03B | $8.39B | $6.86B |
| Net Income |
|
$6.38B | $7.73B | $6.95B | $6.00B |
Thermo Fisher Scientific Balance Sheet
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Cash and Cash Equivalents |
|
$10.33B | $4.48B | $8.52B | $8.08B |
| Inventories |
|
$4.03B | $5.05B | $5.63B | $5.09B |
| Total Current Assets |
|
$21.96B | $20.11B | $25.23B | $24.59B |
| Property,Plant and Equipment |
|
$6.69B | $9.86B | $10.87B | $9.45B |
| Goodwill |
|
$26.04B | $41.92B | $41.20B | $44.02B |
| Total Assets |
|
$69.05B | $95.12B | $97.15B | $98.73B |
| Total Liabilities |
|
$34.54B | $54.15B | $53.01B | $51.88B |
| Retained Earnings |
|
$28.12B | $35.43B | $41.91B | $47.36B |
| Total Shareholder Equity |
|
$34.51B | $40.79B | $43.98B | $46.74B |
| Common Stock |
|
$437.00M | $439.00M | $441.00M | $442.00M |
Thermo Fisher Scientific Cash flow
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Depreciation & Amortization |
|
$2.33B | $2.59B | $3.38B | $3.41B |
| Dividends Payout |
|
-$337.00M | -$395.00M | -$455.00M | -$523.00M |
| Capital Expenditures (Capex) |
|
-$1.47B | -$2.52B | -$2.24B | -$1.48B |
| Free Cash Flow (FCF) |
|
$6.82B | $7.02B | $6.91B | $6.93B |
Thermo Fisher Scientific Profitability
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gross Profit |
|
$16.51B | $20.23B | $19.50B | $17.11B |
| Gross Profit Margin (%) |
|
51.23% | 51.60% | 43.42% | 39.93% |
| Operating Income |
|
$7.79B | $10.03B | $8.39B | $6.86B |
| Operating Income Margin (%) |
|
24.19% | 25.57% | 18.69% | 16.00% |
| Net Income |
|
$6.38B | $7.73B | $6.95B | $6.00B |
| Net Income Margin (%) |
|
19.79% | 19.70% | 15.47% | 13.99% |
| EBITDA |
|
$10.19B | $12.96B | $11.94B | $11.08B |
| EBITDA Margin (%) |
|
31.67% | 31.03% | 26.84% | 25.85% |
Thermo Fisher Scientific Ratios
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Return on Equity (ROE) |
|
18.47% | 18.94% | 15.80% | 12.83% |
| Return on Assets (ROA) |
|
9.23% | 8.12% | 7.15% | 6.07% |
| Debt to Equity |
|
62.99% | 85.03% | 78.42% | 74.70% |
| Debt to total asset |
|
31.48% | 36.46% | 35.50% | 35.36% |
| Enterprise value to revenue |
|
6.08 | 7.48 | 5.38 | 5.41 |
| Enterprise value to EBITDA |
|
19.22 | 22.62 | 20.25 | 20.92 |
| Enterprise value |
|
$195.86B | $293.29B | $241.83B | $231.72B |
| Cash to Debt |
|
38.14% | 27.51% | 26.54% | 24.08% |
| Tax Rate (%) |
|
11.76% | 12.54% | 8.97% | 4.51% |
| Payout Ratio |
|
5.29% | 5.11% | 6.55% | 8.72% |
